Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroshi Kotani

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Signal Transduction and Targeted Therapy|October 2, 2025
Limited SUMOylation inhibitor administration enhances eradication of Burkitt's lymphoma with CD19 CAR-T therapyHiroshi Kotani, Shigeki Sato, Seiji Yano, et al.
Idcases|February 27, 2020
Hidden disseminated extracutaneous AIDS-related Kaposi sarcomaNaoki Kawakami, Ho Namkoong, Masayuki Shimoda, et al.
Idcases|January 29, 2020
IL-6 and G-CSF production resulting from lung cancer in an HIV patientNaoki Kawakami, Ho Namkoong, Katsunori Masaki, et al.
BMC Pulmonary Medicine|December 14, 2018
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case reportAzusa Tanimoto, Shinji Takeuchi, Hiroshi Kotani, et al.
Carcinogenesis|October 3, 2017
Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancerYuta Adachi, Kazuyoshi Watanabe, Kenji Kita, et al.
Medcomm|December 11, 2025
Remarkable Responses to Chemoimmunotherapy in Ultra-Rare Urachal Cancer: A Case Series and Reverse Translational ResearchHiroshi Kotani, Shigeki Sato, Kazuyoshi Shigehara, et al.
Journal of Pharmaceutical Health Care and Sciences|November 12, 2016
Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNAHiroshi Kotani, Koji Sudo, Naoki Hasegawa, et al.
Cancer Discovery|May 8, 2016
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung CancerHidenori Kitai, Hiromichi Ebi, Shuta Tomida, et al.
Frontiers in Oncology|July 23, 2024
Challenges in the treatment of <i>BRAF</i> K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinibAkihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, et al.
Frontiers in Oncology|April 22, 2024
Case report: Navigating treatment pathways for cardiac intimal sarcoma with <i>PDGFRβ</i> N666K mutationAkihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Signal Transduction and Targeted Therapy|October 2, 2025
Limited SUMOylation inhibitor administration enhances eradication of Burkitt's lymphoma with CD19 CAR-T therapyHiroshi Kotani, Shigeki Sato, Seiji Yano, et al.
Idcases|February 27, 2020
Hidden disseminated extracutaneous AIDS-related Kaposi sarcomaNaoki Kawakami, Ho Namkoong, Masayuki Shimoda, et al.
Idcases|January 29, 2020
IL-6 and G-CSF production resulting from lung cancer in an HIV patientNaoki Kawakami, Ho Namkoong, Katsunori Masaki, et al.
BMC Pulmonary Medicine|December 14, 2018
Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case reportAzusa Tanimoto, Shinji Takeuchi, Hiroshi Kotani, et al.
Carcinogenesis|October 3, 2017
Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancerYuta Adachi, Kazuyoshi Watanabe, Kenji Kita, et al.
Medcomm|December 11, 2025
Remarkable Responses to Chemoimmunotherapy in Ultra-Rare Urachal Cancer: A Case Series and Reverse Translational ResearchHiroshi Kotani, Shigeki Sato, Kazuyoshi Shigehara, et al.
Journal of Pharmaceutical Health Care and Sciences|November 12, 2016
Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNAHiroshi Kotani, Koji Sudo, Naoki Hasegawa, et al.
Cancer Discovery|May 8, 2016
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung CancerHidenori Kitai, Hiromichi Ebi, Shuta Tomida, et al.
Frontiers in Oncology|July 23, 2024
Challenges in the treatment of <i>BRAF</i> K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinibAkihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, et al.
Frontiers in Oncology|April 22, 2024
Case report: Navigating treatment pathways for cardiac intimal sarcoma with <i>PDGFRβ</i> N666K mutationAkihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, et al.
Pageof 4